BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Experts in dermatology, medical aesthetics, tissue engineering - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.rbcconsultants.com
X-WR-CALDESC:Events for Experts in dermatology, medical aesthetics, tissue engineering
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260709T190000
DTEND;TZID=America/New_York:20260709T200000
DTSTAMP:20260625T124943Z
CREATED:20260625T124943Z
LAST-MODIFIED:20260625T124943Z
UID:1695-1783623600-1783627200@www.rbcconsultants.com
SUMMARY:Earlier Intervention in HS With COSENTYX® (secukinumab) and Long-Term Impact
DESCRIPTION:Speaker: Leonardo Tjahjono\, MD\, FAAD Board-Certified Dermatologist Assistant Professor of Dermatology Co-Director of Hidradenitis Suppurativa Clinic Director of Inpatient Dermatology George Washington University School of Medicine Washington\, DC \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Earlier Intervention in HS With COSENTYX® (secukinumab) and Long-Term Impact This presentation will review the following key considerations in HS management: – When a patient with HS is ready for biologic therapy – What constitutes “moderate” HS – How patient-reported outcomes aid in HS severity assessment – What earlier intervention with biologic therapy can mean for patients \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/earlier-intervention-in-hs-with-cosentyx-secukinumab-and-long-term-impact/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260714T190000
DTEND;TZID=America/New_York:20260714T200000
DTSTAMP:20260623T120504Z
CREATED:20260623T120504Z
LAST-MODIFIED:20260623T120504Z
UID:1693-1784055600-1784059200@www.rbcconsultants.com
SUMMARY:Choose Fast Relief From Hives and Itch With RHAPSIDO®
DESCRIPTION:Speaker: Michael J. Payette\, MD\, MBA\, FAAD Co-Founder and Dermatologist\, Central Connecticut Dermatology Dermatologist\, Middlesex Health Associate Editor\, Dermatology In-Review Cromwell\, Connecticut \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Choose Fast Relief From Hives and Itch With RHAPSIDO®: An Oral Targeted Treatment Approach for Uncontrolled Chronic Spontaneous Urticaria Despite Antihistamine Use. This presentation will explore a different approach in patient care with RHAPSIDO by explaining the role of Bruton’s tyrosine kinase (BTK) in CSU pathophysiology and MOA of RHAPSIDO as the first-of-its-kind oral BTK inhibitor (BTKi) therapy\, exploring clinical data on RHAPSIDO\, including efficacy\, safety\, and onset of action\, to support informed treatment decisions after antihistamines fall short\, and providing real-world perspectives from expert peers on how RHAPSIDO may help your appropriate patients. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/choose-fast-relief-from-hives-and-itch-with-rhapsido-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260720T190000
DTEND;TZID=America/New_York:20260720T200000
DTSTAMP:20260708T112151Z
CREATED:20260708T112014Z
LAST-MODIFIED:20260708T112151Z
UID:1699-1784574000-1784577600@www.rbcconsultants.com
SUMMARY:A Joint Approach to Psoriatic Disease Management: Bimzlex for your Patients with PsO and PsA
DESCRIPTION:Speakers: Saakshi Khattri\, MD\, MBBS\, FAAD\, FACR Director\, Dermatology/Rheumatology Service Icahn School of Medicine\, Mount Sinai  New York\, New York and Gordan K. Lam MD Board-Certified Rheumatologist Atrium Health Carolinas Medical Center \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: A Joint Approach to Psoriatic Disease Management: Bimzlex for your Patients with PsO and PsA. Bimzelx is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy\, active psoriatic arthritis\, active non radiographic axial spondyloarthritis with objective signs of inflammation\, active ankylosing spondylitis\, and moderate to severe hidradenitis suppurativa. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/a-joint-approach-to-psoriatic-disease-management-bimzlex-for-your-patients-with-pso-and-psa/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260723T190000
DTEND;TZID=America/New_York:20260723T200000
DTSTAMP:20260708T111130Z
CREATED:20260708T111130Z
LAST-MODIFIED:20260708T111130Z
UID:1697-1784833200-1784836800@www.rbcconsultants.com
SUMMARY:Bridging Care Across Skin & Joints: An Option to Choose TREMFYA First
DESCRIPTION:Speaker: Adrian Rodriguez\, MD Board Certified Dermatologist Nashville Skin: Comprehensive Dermatology Center Advanced Research Experts\, PLC Adjunct Clinical Faculty\, University of Tennessee Health Science Center Nashville\, Tennessee \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Bridging Care Across Skin & Joints: An Option to Choose TREMFYA First \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/bridging-care-across-skin-joints-an-option-to-choose-tremfya-first/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260728T190000
DTEND;TZID=America/New_York:20260728T200000
DTSTAMP:20260721T171935Z
CREATED:20260721T171935Z
LAST-MODIFIED:20260721T171935Z
UID:1702-1785265200-1785268800@www.rbcconsultants.com
SUMMARY:Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies
DESCRIPTION:Speakers: Ali Shahbaz\, MD\, FAAD\, FRCPC and Tina Bhutani\, MD\, MAS \nModerator: Leon Kircik\, MD\, FAAD Medical Director\, International Dermatology Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai\, New York\, NY Indiana University Medical Center\, Indianapolis\, IN Medical Director Physicians Skin Care\, PLLC\, Louisville\, KY DermResearch\, PLLC\, Louisville\, KY Skin Sciences\, PLLC\, Louisville\, KY \nPlease join us for our next IDF Educational Series Webinar: Advancing Care in Moderate-to-Severe Atopic Dermatitis: Disease Insights and Emerging Targeted Therapies. Deeper Understanding of Atopic Dermatitis This educational webinar will provide an overview of moderate-to-severe atopic dermatitis as a chronic\, relapsing inflammatory disease driven by underlying type 2 immune dysregulation and skin barrier dysfunction. Ali Shahbaz\, MD\, FAAD\, FRCPC will review the clinical presentation\, disease burden\, and impact on patients’ quality of life\, including pruritus\, sleep disturbance\, and psychosocial effects. The session will also highlight current challenges in disease management and ongoing unmet needs\, offering insights to support a deeper understanding of atopic dermatitis and inform clinical decision-making. EBGLYSS®(lebrikizumab-lbkz): What could less mean for your patients? Join your colleagues for a peer discussion exploring the latest EBGLYSS data. This program is sponsored by\, and the speaker is presenting on behalf of\, Lilly USA\, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Please see Prescribing Information and Patient Information at the product theater or on https://ebglyss.lilly.com. Please see Instructions for use included with the device. EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company\, its subsidiaries\, or affiliates. \n  \nREGISTER
URL:https://www.rbcconsultants.com/event/advancing-care-in-moderate-to-severe-atopic-dermatitis-disease-insights-and-emerging-targeted-therapies-2/
END:VEVENT
END:VCALENDAR